Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 80
Filtrar
Más filtros

Medicinas Complementárias
Tipo del documento
Intervalo de año de publicación
1.
Drug Deliv Transl Res ; 9(2): 508-519, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-29181832

RESUMEN

Composite film dressings composed of pluronic F127 (PL)-pectin (PC) and pluronic (PL) F127-gelatin (GL) were investigated as potential drug delivery system for wound healing. Composite films were solvent cast by blending PL with PC or GL in different ratios using glycerol (2.5%) as plasticizer. Erythromycin (ER) (0.1%) was incorporated in films as model hydrophobic antibiotic. The optimized composite films were characterized for physical appearance, morphology, mechanical profile, and thermal behavior. In addition, drug release, antibacterial activity, and cytocompatibility of the films were investigated to assess their potential as drug delivery system. The composite films exhibited excellent wound dressing characters in terms of appearance, stability, and mechanical profile. Moreover, ER-loaded composite films released ER in controlled manner, exhibited antibacterial activity against Staphylococcus aureus, and were non-toxic to human skin fibroblast. These findings demonstrate that these composite films hold the potential to be formulated as antibacterial wound dressing.


Asunto(s)
Antibacterianos/administración & dosificación , Vendajes , Sistemas de Liberación de Medicamentos , Eritromicina/administración & dosificación , Poloxámero/administración & dosificación , Antibacterianos/química , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Liberación de Fármacos , Eritromicina/química , Fibroblastos/efectos de los fármacos , Gelatina/administración & dosificación , Gelatina/química , Humanos , Pectinas/administración & dosificación , Pectinas/química , Poloxámero/química , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/crecimiento & desarrollo , Cicatrización de Heridas/efectos de los fármacos
2.
Fish Shellfish Immunol ; 84: 434-440, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30308294

RESUMEN

The global abuse and misuse of antibiotics in the treatment and prevention of bacterial infections has resulted in the ubiquitous existence of these drugs in aquatic environments, which causes frequent antimicrobial resistance and pollution in ecosystems. However, the chronic effects of antimicrobial agents on aquatic animal growth and health have not been fully evaluated. In the present study, three typical antibiotics (tetracycline, erythromycin, and norfloxacin) were administered orally to juvenile sea cucumbers Apostichopus japonicus for 45 days, to mimic the long-term use of antibiotics. As a result, tetracycline and erythromycin promoted the growth and digestive activity of lipase, pepsin, and trypsin, but norfloxacin did not show significant prompting effect on digestive activity and even retarded the weight gain of the sea cucumbers. The mortality was higher in antibiotic treated groups between the 2nd and 4th days after challenge with Vibrio splendidus. At the same time, lower immune-related parameters were found in antibiotic feeding juveniles, suggesting that the use of antibiotics might weaken the immune defense system of sea cucumbers. This study revealed that antibiotic administration could facilitate the growth of sea cucumbers to varying degrees yet coupled with high risks of impaired immune function and compromised disease resistance.


Asunto(s)
Antibacterianos/farmacología , Eritromicina/farmacología , Inmunidad Innata/efectos de los fármacos , Norfloxacino/farmacología , Stichopus/efectos de los fármacos , Tetraciclina/farmacología , Alimentación Animal/análisis , Animales , Antibacterianos/administración & dosificación , Dieta , Suplementos Dietéticos/análisis , Eritromicina/administración & dosificación , Intestinos/efectos de los fármacos , Intestinos/enzimología , Norfloxacino/administración & dosificación , Stichopus/enzimología , Stichopus/crecimiento & desarrollo , Stichopus/inmunología , Tetraciclina/administración & dosificación , Vibrio/fisiología
3.
Phytother Res ; 31(3): 410-417, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-28124400

RESUMEN

Acne vulgaris, a chronic condition associated with overgrowth of Propionibacterium acnes and Staphylococcus epidermidis, is commonly treated with antibiotics. However, the emergence of antibiotic resistance has resulted in a need for alternative therapies. The aim of this study is to develop a topical preparation incorporating essential oils (EOs) for use against acne-associated bacteria and assess its efficacy against prescription therapies Dalacin T and Stiemycin. Antimicrobial screening of rosewood, clove bud and litsea EOs was conducted before interactions between binary and ternary combinations were determined against P. acnes and S. epidermidis (type and clinical isolates) using minimum inhibitory concentrations and fractional inhibitory concentrations. The EOs were characterised by both gas chromatography-mass spectrometry and nuclear magnetic resonance. A combination of 0.53 mg/mL litsea, 0.11 mg/mL rosewood and 0.11 mg/mL clove bud was formulated into herbal distillates and compared with Dalacin T and Stiemycin against antibiotic sensitive and resistant isolates (erythromycin). The distillate with EO had synergistic activity against P. acnes (7log10 reduction) and indifferent activity against S. epidermidis (6log10 reduction); antimicrobial activity was either significantly (p ≤ 0.05) more antimicrobial or equivalent to that of Dalacin T and Stiemycin. This formulation may serve as a valuable alternative for the control of acne vulgaris-associated bacteria. Copyright © 2017 John Wiley & Sons, Ltd.


Asunto(s)
Acné Vulgar/microbiología , Antibacterianos/administración & dosificación , Aceites Volátiles/administración & dosificación , Aceites Volátiles/farmacología , Propionibacterium acnes/efectos de los fármacos , Staphylococcus epidermidis/efectos de los fármacos , Acné Vulgar/tratamiento farmacológico , Administración Tópica , Antibacterianos/farmacología , Antiinfecciosos/administración & dosificación , Clindamicina/administración & dosificación , Clindamicina/farmacología , Combinación de Medicamentos , Sinergismo Farmacológico , Eritromicina/administración & dosificación , Eritromicina/farmacología , Cromatografía de Gases y Espectrometría de Masas , Humanos , Pruebas de Sensibilidad Microbiana , Aceites Volátiles/química , Propionibacterium acnes/crecimiento & desarrollo , Staphylococcus epidermidis/crecimiento & desarrollo
4.
Biomed Res Int ; 2016: 4020715, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27413745

RESUMEN

Staphylococcus epidermidis (S. epidermidis) is an opportunistic pathogen with low pathogenicity and a cause of the repeated outbreak of bovine mastitis in veterinary clinical settings. In this report, a biofilm model of S. epidermidis was generated and the minimal inhibitory concentration (MIC) and sub-MIC (SMIC) on bacterial cultures were assessed for the following agents: total alkaloids of Sophora alopecuroides (TASA), ciprofloxacin (CIP), and erythromycin (ERY). The formation and characteristic parameters of biofilm were analyzed in terms of XTT assay, silver staining, and confocal laser scanning microscope (CLSM). Results showed that a sub-MIC of TASA could inhibit 50% biofilm of bacterial activity, while 250-fold MIC of CIP and ERY MICs only inhibited 50% and 47% of biofilm formation, respectively. All three agents could inhibit the biofilm formation at an early stage, but TASA showed a better inhibitory effect on the late stage of biofilm thickening. A morphological analysis using CLSM further confirmed the destruction of biofilm by these agents. These results thus suggest that TASA has an inhibitory effect on biofilm formation of clinic S. epidermidis, which may be a potential agent warranted for further study on the treatment prevention of infection related to S. epidermidis in veterinary clinic.


Asunto(s)
Alcaloides/administración & dosificación , Biopelículas/crecimiento & desarrollo , Ciprofloxacina/administración & dosificación , Sophora/química , Staphylococcus epidermidis/efectos de los fármacos , Staphylococcus epidermidis/crecimiento & desarrollo , Antibacterianos/administración & dosificación , Apoptosis/efectos de los fármacos , Biopelículas/efectos de los fármacos , Eritromicina/administración & dosificación , Extractos Vegetales/administración & dosificación , Sophora/clasificación , Especificidad de la Especie , Staphylococcus epidermidis/citología
5.
Brain Inj ; 26(9): 1113-7, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22571511

RESUMEN

OBJECTIVE: To evaluate the tolerance to enteral nutrition (EN) and the effects of pro-kinetic drugs in critical traumatic brain injury (TBI) patients. METHODS: Transversal observational study. A total of 32 out of 45 TBI patients of both genders receiving EN were evaluated in a trauma referral hospital intensive care unit (ICU). Data from each patient were collected for a period of 10 consecutive days after initiation of enteral feeding: gastric residue, presence of vomiting, abdominal distension, Glasgow coma scale and the use of pro-kinetic agents. RESULTS: In 20 of the 32 patients high levels of gastric residue were found. Of these 20 patients, half could not tolerate the diet within the first 72 hours following infusion. However, no association was found between disease severity and occurrence of gastrointestinal complications (p > 0.05). Feeding intolerance was observed in 75.0% (n = 24) of patients, even with the systematic use of metaclopramide from the outset of nutritional therapy. All patients with feeding intolerance who used erythromycin by nasogastric tube showed improvement. CONCLUSIONS: The high level of gastric residue was the most common feeding intolerance and the delivery of erythromycin by nasogastric tube seems to control gastrointestinal disorders in TBI patients.


Asunto(s)
Antieméticos/administración & dosificación , Lesiones Encefálicas/fisiopatología , Domperidona/administración & dosificación , Nutrición Enteral/efectos adversos , Eritromicina/administración & dosificación , Trastornos de la Motilidad Esofágica/fisiopatología , Metoclopramida/administración & dosificación , Vómitos/prevención & control , Adulto , Anciano , Lesiones Encefálicas/complicaciones , Lesiones Encefálicas/terapia , Estudios Transversales , Trastornos de la Motilidad Esofágica/tratamiento farmacológico , Trastornos de la Motilidad Esofágica/etiología , Femenino , Escala de Coma de Glasgow , Humanos , Unidades de Cuidados Intensivos , Intubación Gastrointestinal/efectos adversos , Intubación Gastrointestinal/métodos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Vómitos/tratamiento farmacológico , Adulto Joven
6.
Neuro Endocrinol Lett ; 32 Suppl 1: 131-6, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22167215

RESUMEN

OBJECTIVES: Electrogastrography (EGG) is a non-invasive investigation of gastric myoelectrical activity. The aim of study was to evaluate the impact of erythromycin on EGG in gastrointestinal toxic injury induced by dextran sodium sulphate (DSS) in experimental pigs. METHODS: The experiments were carried out on 12 adult pigs (weighing 30-35 kg). EGG was recorded using Digitrapper equipment (Synectics Medical AB, Stockholm). Running spectrum activity was used for EGG evaluation. There were two groups of animals: Group I: 6 controls with erythromycin administration (1,600 mg intragastrically); Group II: 6 animals treated with DSS (for 5 days, 0.25 g/kg per day in a dietary bolus) followed by erythromycin administration. Baseline and subsequent six separate 30-minute EGG-recordings (from time 0 to 360 min) were accomplished in each animal. RESULTS AND CONCLUSION: A total of 84 records were analysed. Baseline dominant frequency of slow waves was fully comparable in both groups. In Group I, there was a significant increase in dominant frequency after erythromycin administration (maximum between 240-360 min). There was a flat non-significant and delayed increase in dominant frequency after erythromycin administration in Group II. The difference between Group I and II at particular time intervals was not significant but a diverse trend was evident. EGG recording enables us to register a gastric myoelectrical effect of prokinetic drugs. Erythromycin induced a significant increase in the dominant frequency of slow waves. DSS caused toxic injury to the porcine gastrointestinal tract responsible for the delayed and weaker myoelectrical effect of erythromycin in experimental animals.


Asunto(s)
Sulfato de Dextran , Eritromicina/farmacología , Enfermedades Gastrointestinales/inducido químicamente , Enfermedades Gastrointestinales/fisiopatología , Estómago/efectos de los fármacos , Estómago/fisiología , Animales , Evaluación Preclínica de Medicamentos , Electromiografía/métodos , Electromiografía/veterinaria , Fenómenos Electrofisiológicos/efectos de los fármacos , Eritromicina/administración & dosificación , Femenino , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/farmacología , Tracto Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/lesiones , Modelos Animales , Estómago/lesiones , Sus scrofa
7.
Gastrointest Endosc Clin N Am ; 21(4): 681-96, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21944418

RESUMEN

Upper gastrointestinal (UGI) bleeding secondary to ulcer disease occurs commonly and results in significant patient morbidity and medical expense. After initial resuscitation, carefully performed endoscopy provides an accurate diagnosis of the source of the UGI hemorrhage and can reliably identify those high-risk subgroups that may benefit most from endoscopic hemostasis. Effective endoscopic hemostasis of ulcer bleeding can significantly improve outcomes by reducing rebleeding, transfusion requirement, and need for surgery, as well as reduce the cost of medical care. This article discusses the important aspects of the diagnosis and treatment of bleeding from ulcers, with a focus on endoscopic therapy.


Asunto(s)
Hemostasis Endoscópica , Úlcera Péptica Hemorrágica/terapia , Terapia Combinada , Electrocoagulación/métodos , Endoscopía Gastrointestinal , Epinefrina/administración & dosificación , Eritromicina/administración & dosificación , Humanos , Hipertermia Inducida/métodos , Úlcera Péptica Hemorrágica/diagnóstico , Resucitación/métodos , Medición de Riesgo , Instrumentos Quirúrgicos , Adhesivos Tisulares/administración & dosificación , Ultrasonografía Doppler
8.
Nutrition ; 27(5): 509-12, 2011 May.
Artículo en Inglés | MEDLINE | ID: mdl-21295944

RESUMEN

The provision of early nutrition therapy to critically ill patients is established as the standard of care in most intensive care units around the world. Despite the known benefits, tolerance of enteral nutrition in the critically ill varies and delivery is often interrupted. Observational research has demonstrated that clinicians deliver little more than half of the enteral nutrition they plan to provide. The main clinical tool for assessing gastric tolerance is gastric residual volume; however, its usefulness in this setting is debated. There are several strategies employed to improve the tolerance and hence adequacy of enteral nutrition delivery in the critically ill. One of the most widely used strategies is that of prokinetic drug administration, most commonly metoclopramide and erythromycin. Although there are new agents being investigated, none are ready for routine application in the critically ill and the benefits are still being established. This review investigates current practice and considers the literature on assessment of enteral tolerance and optimization of enteral nutrition in the critically ill.


Asunto(s)
Nutrición Enteral/normas , Vaciamiento Gástrico , Fármacos Gastrointestinales/uso terapéutico , Unidades de Cuidados Intensivos/normas , Estómago/fisiopatología , Enfermedad Crítica/terapia , Eritromicina/administración & dosificación , Eritromicina/uso terapéutico , Mucosa Gástrica/metabolismo , Fármacos Gastrointestinales/administración & dosificación , Humanos , Metoclopramida/administración & dosificación , Metoclopramida/uso terapéutico , Nivel de Atención
9.
Eye Contact Lens ; 35(5): 268-71, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19657280

RESUMEN

OBJECTIVE: The purpose of this case report is to explore the diagnosis and the treatment of a complication secondary to a radial keratotomy (RK) surgery. It illustrates the fact that, even more than 20 years after the procedure, corneas that underwent RK procedures may still be at risk for complications. METHODS: The patient was seen in emergency department in September 2008 for a red and painful eye. Examination revealed a separation of one RK incision consequent to heavy eye rubbing. Treatment initiated for this condition is similar to treatment of minor corneal erosion and is explained. RESULTS: After intensive lubrication, the condition healed in 2 weeks, without further complications. CONCLUSION: It is shown that patients after RK remain at risk for corneal complications over the years after their initial surgical procedures. Patients should be educated about the fragility of their cornea and globe and to do not rub their eyes. Eye care practitioners should reinforce these messages periodically. A close follow-up of post-RK patients is needed to keep these patients in optimal ocular health.


Asunto(s)
Ojo , Queratotomía Radial/efectos adversos , Masaje/efectos adversos , Dehiscencia de la Herida Operatoria/etiología , Administración Tópica , Adulto , Antibacterianos/administración & dosificación , Profilaxis Antibiótica , Eritromicina/administración & dosificación , Humanos , Lubricantes/uso terapéutico , Masculino , Soluciones Oftálmicas/uso terapéutico , Dolor/etiología , Periodo Posoperatorio , Dehiscencia de la Herida Operatoria/tratamiento farmacológico , Dehiscencia de la Herida Operatoria/fisiopatología , Lágrimas/metabolismo , Factores de Tiempo , Agudeza Visual , Cicatrización de Heridas
10.
J Diabetes Complications ; 22(5): 339-47, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18413164

RESUMEN

AIMS: This study was conducted to evaluate the suitability of a new minipig model for investigating aspects of diabetes such as delayed gastric emptying and glucose metabolism abnormalities, and to test the effects of mitemcinal (GM-611), an orally active erythromycin-derived motilin receptor agonist, on gastric emptying and postprandial glucose in normal and diabetic minipigs. METHODS AND RESULTS: Intravenous injection of 300 mg/kg streptozotocin (STZ) to 5-week-old minipigs induced moderate hyperglycemia (about 200 mg/dl) for >80 weeks without insulin treatment. Decreased insulin production (P<.05), increased area under the glucose curve (P<.05), and slower glucose disappearance (P<.05) were demonstrated, and there was no severe inhibition of body weight gain, liver failure, or renal failure. Gastric emptying was significantly delayed in diabetic minipigs (P<.05) at 80 weeks, but not at 40 weeks, post-STZ. Oral administration of mitemcinal (5 mg/kg) at 80 weeks accelerated gastric emptying and induced a similar postprandial glucose profile in normal and diabetic minipigs with delayed gastric emptying. CONCLUSIONS: The new diabetic minipig model showed suitability for investigating diabetes, gastric emptying, and plasma glucose excursions. Since delayed gastric emptying and irregular plasma glucose excursions are characteristic of diabetic gastroparesis, the accelerating and regulating effects of mitemcinal on this model add to the existing evidence that mitemcinal is likely to be useful for treating diabetic gastroparesis.


Asunto(s)
Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/complicaciones , Eritromicina/análogos & derivados , Vaciamiento Gástrico/efectos de los fármacos , Gastroparesia/tratamiento farmacológico , Periodo Posprandial/efectos de los fármacos , Administración Oral , Animales , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/tratamiento farmacológico , Diabetes Mellitus Experimental/fisiopatología , Evaluación Preclínica de Medicamentos , Eritromicina/administración & dosificación , Eritromicina/farmacología , Eritromicina/uso terapéutico , Vaciamiento Gástrico/fisiología , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/farmacología , Fármacos Gastrointestinales/uso terapéutico , Gastroparesia/inducido químicamente , Gastroparesia/fisiopatología , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/fisiopatología , Riñón/efectos de los fármacos , Riñón/fisiopatología , Hígado/efectos de los fármacos , Hígado/fisiopatología , Masculino , Periodo Posprandial/fisiología , Estreptozocina , Porcinos , Porcinos Enanos
11.
BMJ ; 336(7638): 266-8, 2008 Feb 02.
Artículo en Inglés | MEDLINE | ID: mdl-18184631

RESUMEN

OBJECTIVE: To investigate the impact of zinc supplementation in children with cholera. DESIGN: Double blind, randomised, placebo controlled trial. SETTING: Dhaka Hospital, Bangladesh. PARTICIPANTS: 179 children aged 3-14 years with watery diarrhoea and stool dark field examination positive for Vibrio cholerae and confirmed by stool culture. INTERVENTION: Children were randomised to receive 30 mg elemental zinc per day (n=90) or placebo (n=89) until recovery. All children received erythromycin suspension orally in a dose of 12.5 mg/kg every six hours for three days. MAIN OUTCOME MEASURES: Duration of diarrhoea and stool output. Results 82 children in each group completed the study. More patients in the zinc group than in the control group recovered by two days (49% v 32%, P=0.032) and by three days (81% v 68%, P=0.03). Zinc supplemented patients had 12% shorter duration of diarrhoea than control patients (64.1 v 72.8 h, P=0.028) and 11% less stool output (1.6 v 1.8 kg/day, P=0.039). CONCLUSION: Zinc supplementation significantly reduced the duration of diarrhoea and stool output in children with cholera. Children with cholera should be supplemented with zinc to reduce its duration and severity. TRIAL REGISTRATION: Clinical trials NCT00226616.


Asunto(s)
Cólera/tratamiento farmacológico , Suplementos Dietéticos , Zinc/administración & dosificación , Adolescente , Antibacterianos/administración & dosificación , Bangladesh , Niño , Preescolar , Diarrea/prevención & control , Método Doble Ciego , Quimioterapia Combinada , Eritromicina/administración & dosificación , Humanos , Lactante , Resultado del Tratamiento
12.
Intern Med ; 46(7): 353-7, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17409596

RESUMEN

BACKGROUND: Erythromycin (EM) and rifampicin (RFP) have mainly been used to treat patients with Legionella pneumonia. Since intravenous ciprofloxacin (CPFX) became available in Japan from 2000, many reports have been published detailing successful treatment of Legionella pneumonia with CPFX. In this study, we compared the evolution of patients with Legionella pneumonia treated with CPFX to those treated with EM. METHODS: The study included nine patients treated with CPFX and eighteen patients treated with EM. Diagnosis of these patients was made by culture, PCR, urinary antigen assay or a serological method. A comparison was made of the patients' characteristics, severity of pneumonia, efficacy of each agent and the clinical course. RESULTS: No significant differences were observed between the two groups, in regard to age, gender, underlying disease or severity of pneumonia. In addition, the period of time from onset of the disease until appropriate therapy did not differ significantly between the two groups. In the CPFX group, all of the patients were cured and in the EM group 16 out of the 18 patients were cured. Although there were no significant differences, the time to apyrexia, normalization of leukocytosis and a 50% decrease in C-reactive protein (CRP) occurred within a relatively shorter time frame in the CPFX group than in the EM group (3.5 versus 4 days, 4 versus 5.2 days, and 2.9 versus 10.3 days, respectively). And, the duration of antibiotic treatment in the CPFX group was significantly shorter than in the EM group. CONCLUSION: CPFX was as effective as erythromycin in the treatment of Legionella pneumonia. The effects of treatment may appear relatively earlier and the duration of treatment was significantly shorter in patients treated with CPFX therapy than with EM therapy.


Asunto(s)
Ciprofloxacina/administración & dosificación , Eritromicina/administración & dosificación , Enfermedad de los Legionarios/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Cohortes , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Estudios de Seguimiento , Humanos , Infusiones Intravenosas , Japón/epidemiología , Enfermedad de los Legionarios/diagnóstico , Enfermedad de los Legionarios/epidemiología , Masculino , Persona de Mediana Edad , Probabilidad , Estudios Retrospectivos , Medición de Riesgo , Índice de Severidad de la Enfermedad , Estadísticas no Paramétricas , Resultado del Tratamiento
13.
Antibiot Khimioter ; 51(9-10): 13-7, 2006.
Artículo en Ruso | MEDLINE | ID: mdl-18030786

RESUMEN

The method of cell-associated antibiotic therapy consists of extracorporal exposure of the autoblood formed elements to antibiotic solution followed by their reinfusion. Pharmacokinetics of erythromycin after its intravenous and cell-associated administration in patients with community-acquired pneumonia and the clinical efficacy of the method were evaluated. HPLC of the erythromycin pharmacokinetic pattern in 20 patients showed that after the antibiotic target transport the pharmacokinetic model changed from one-compartment to two-compartment one and the antibiotic maximum concentration and elimination rate were lower vs. the intravenous administration. It was also shown that the clinical efficacies of the erythromycin intravenous administration and target transport did not significantly differ, whereas after the cell-associated transport of the antibiotic the therapeutic effect was observed earlier and the side effects were less frequent.


Asunto(s)
Antibacterianos/farmacocinética , Transfusión de Sangre Autóloga , Eritromicina/farmacocinética , Neumonía/metabolismo , Adulto , Antibacterianos/administración & dosificación , Antibacterianos/metabolismo , Células Sanguíneas/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Eritromicina/administración & dosificación , Eritromicina/metabolismo , Femenino , Humanos , Infusiones Intravenosas , Masculino , Neumonía/tratamiento farmacológico
14.
Clin Infect Dis ; 41(12): 1697-705, 2005 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-16288390

RESUMEN

BACKGROUND: Although third-generation cephalosporins, such as ceftriaxone (CTRX), and pneumococcal fluoroquinolones, such as moxifloxacin (MXF), are currently recommended first-line antibiotics for empirical treatment of inpatients with community-acquired pneumonia, CTRX and MXF have never undergone a head-to-head comparison. We therefore compared the efficacy, safety, and speed and quality of defervescence of sequential intravenous or oral MXF and high-dose CTRX with or without erythromycin (CTRX+/-ERY) for patients with community-acquired pneumonia requiring parenteral therapy. METHODS: In this prospective, multicenter, randomized, controlled, nonblinded study, 397 patients were randomly assigned to receive either MXF (400 mg once daily intravenously, possibly followed by oral tablets) or CTRX (2 g intravenously once daily) with or without ERY (1 g intravenously every 6-8 h) for 7-14 days. RESULTS: Among 317 patients evaluable for efficacy and safety, 138 (85.7%) of 161 MXF-treated patients and 135 (86.5%) of 156 CTRX+/-ERY-treated patients (59 [37.8%] of whom received CTRX and ERY) achieved continued clinical resolution. Defervescence and relief of symptoms, such as chest pain, occurred significantly earlier in the MXF-treated group than in the CTRX+/-ERY-treated group. Both regimens were generally well tolerated. CONCLUSIONS: For adult patients hospitalized with community-acquired pneumonia, sequential MXF therapy was clinically equivalent to high-dose CTRX+/-ERY therapy but led to a faster clinical improvement.


Asunto(s)
Antibacterianos/administración & dosificación , Compuestos Aza/administración & dosificación , Ceftriaxona/administración & dosificación , Eritromicina/administración & dosificación , Hospitalización , Neumonía Bacteriana/tratamiento farmacológico , Quinolinas/administración & dosificación , Administración Oral , Anciano , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Quimioterapia Combinada , Femenino , Fluoroquinolonas , Humanos , Inyecciones Intravenosas , Masculino , Moxifloxacino , Nutrición Parenteral , Estudios Prospectivos , Inducción de Remisión , Factores de Tiempo
16.
J Antimicrob Chemother ; 56(4): 783-6, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16144869

RESUMEN

OBJECTIVE: To evaluate the effect of delayed administration of erythromycin in the course of acute otitis media caused by an erythromycin-susceptible Streptococcus pneumoniae strain in the gerbil model. METHODS: The bacterium was inoculated by transbullar challenge in the middle ear (ME) and antibiotic treatment at different doses was administered at various times thereafter. RESULTS: When 2.5 mg/kg of erythromycin was administered as a single dose 2, 5, 18 or 21 h post-inoculation (pi) the bacterial eradication rate was 55, 40, 0 and 0%, respectively. A higher dose (5 mg/kg) administered also as a single dose 2, 5, 18 and 21 h pi achieved bacterial eradication rates of 62.5, 43.8, 0 and 0%, respectively. Using a very high dose (50 mg/kg) repeated three times at 3 h intervals (total dose 150 mg/kg) and starting the treatment 21 h pi only achieved bacterial eradication in 25% of cases. The concentration of erythromycin achieved in the ME 90 min after administration of 5 mg/kg 5 or 21 h pi was very similar (0.74 and 0.79 mg/L) but the ME half-life was longer (98.2 min) with the early administration as compared with the delayed form (47.5 min), which could partially explain the different results. Further experiments showed that the failures observed with the delayed administration were not related to the time elapsed from antibiotic administration to ME sampling or selection of antibiotic-resistant mutants. CONCLUSION: Bacteriological and clinical efficacies were significantly diminished if antibiotic administration was delayed.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Eritromicina/administración & dosificación , Eritromicina/uso terapéutico , Otitis Media/tratamiento farmacológico , Infecciones Neumocócicas/tratamiento farmacológico , Animales , Antibacterianos/sangre , Antibacterianos/farmacocinética , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Eritromicina/sangre , Eritromicina/farmacocinética , Gerbillinae , Pruebas de Sensibilidad Microbiana , Factores de Tiempo , Resultado del Tratamiento
18.
Toxicol Appl Pharmacol ; 205(1): 43-52, 2005 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-15885263

RESUMEN

Ulcerative colitis is a common inflammatory bowel disease (IBD) of unknown etiology. Recent studies have revealed the role of some microorganisms in the initiation and perpetuation of IBD. The role of antibiotics in the possible modulation of colon inflammation is still uncertain. In this study, we evaluated the effects of two macrolides, namely azithromycin and erythromycin, at different doses on the extent and severity of ulcerative colitis caused by intracolonic administration of 3% acetic acid in rats. The lesions and the inflammatory response were assessed by histology and measurement of myeloperoxidase (MPO) activity, nitric oxide synthetase (NOS) and tumor necrosis factor alpha (TNFalpha) in colonic tissues. Inflammation following acetic acid instillation was characterized by oedema, diffuse inflammatory cell infiltration and necrosis. Increase in MPO, NOS and TNFalpha was detected in the colonic tissues. Administration of either azithromycin or erythromycin at different dosage (10, 20 and 40 mg/kg orally, daily for 5 consecutive days) significantly (P < 0.05) reduced the colonic damage, MPO and NOS activities as well as TNFalpha level. This reduction was highly significant with azithromycin when given at a dose of 40 mg/kg. It is concluded that azithromycin and erythromycin may have a beneficial therapeutic role in ulcerative colitis.


Asunto(s)
Azitromicina/uso terapéutico , Colitis Ulcerosa/tratamiento farmacológico , Eritromicina/uso terapéutico , Ácido Acético/administración & dosificación , Ácido Acético/efectos adversos , Animales , Azitromicina/administración & dosificación , Azitromicina/metabolismo , Colitis Ulcerosa/inducido químicamente , Colitis Ulcerosa/metabolismo , Colon/efectos de los fármacos , Colon/enzimología , Colon/fisiopatología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Eritromicina/administración & dosificación , Eritromicina/metabolismo , Interferón gamma/antagonistas & inhibidores , Interferón gamma/efectos de los fármacos , Interferón gamma/metabolismo , Masculino , Óxido Nítrico Sintasa/antagonistas & inhibidores , Óxido Nítrico Sintasa/efectos de los fármacos , Óxido Nítrico Sintasa/metabolismo , Peroxidasa/antagonistas & inhibidores , Peroxidasa/química , Peroxidasa/metabolismo , Ratas , Ratas Wistar , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/química , Factor de Necrosis Tumoral alfa/metabolismo
19.
Tohoku J Exp Med ; 201(3): 157-63, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14649737

RESUMEN

We isolated five bacterial strains from patients diagnosed as having nocardiosis. Bacterial species were identified based on the similarities in the nucleotide sequences of 16S ribosomal RNAs. Three of the five strains were identified as Nocardia asteroids, but unexpectedly other two were Streptomyces hygroscopicus and Rothia dentocariosa. The latter two species are not members of the family Nocardiaceae. We investigated the susceptibilities of these five strains to the following nine antimicrobial agents: trimethoprim/sulfamethoxazole (TMP/SMX), minocycline (MINO), erythromycin (EM), amikacin (AMK), cefotaxime (CTX), faropenem (FRPM), imipenem (IPM), ciprofloxacin (CPFX), and sparfloxacin (SPFX). The minimum inhibitory concentration (MIC) ranges (mg/ml) were as follows: TMP-SMX, 4- > 32; MINO, 0.125-8; EM, < or = 0.016- > 32; AMK, 1-2; CTX, 0.063- > 32; FRPM, 0.063-16; IPM, 0.125-2; CPFX, 4-32; and SPFX, 0.5-16. Moreover, the synergistic effects of AMK in combination with each of TMP-SMX, MINO, EM, CTX, IPM, and SPFX were investigated by checkerboard synergy testing. No antagonism was recognized for the three N. asteroides strains. Synergistic and additive effects were observed for the combinations of AMK with CTX, IPM, or SPFX.


Asunto(s)
Amicacina/administración & dosificación , Quimioterapia Combinada/uso terapéutico , Nocardiosis/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Cefotaxima/administración & dosificación , Ciprofloxacina/administración & dosificación , ADN Ribosómico/metabolismo , Eritromicina/administración & dosificación , Femenino , Fluoroquinolonas/farmacología , Bacterias Grampositivas/metabolismo , Humanos , Imipenem/administración & dosificación , Lactamas/administración & dosificación , Masculino , Persona de Mediana Edad , Minociclina/administración & dosificación , Nocardia/metabolismo , ARN Ribosómico 16S/metabolismo , Streptomyces/metabolismo , Sulfametoxazol/administración & dosificación , Trimetoprim/administración & dosificación , beta-Lactamas
20.
Nihon Kokyuki Gakkai Zasshi ; 41(4): 261-7, 2003 Apr.
Artículo en Japonés | MEDLINE | ID: mdl-12795180

RESUMEN

To evaluate the efficacy of Switch therapy for community-acquired pneumonia, we conducted a prospective randomized controlled study in thirty-two hospitalized patients. These cases corresponded to Fine's risk classes II to IV. Using a table of random numbers, sixteen patients were assigned to a Switch therapy group, and the other sixteen, to a clinical pathway group. Both groups initially received intravenous antimicrobials. Within the Switch therapy group, when all the patients were afebrile for more than sixteen hours, their intravenous antimicrobials were switched to oral, and the patients were discharged on the following day. For all patients in the clinical pathway group, the critical pathway was defined as an eight-day planned hospitalization, with a time-task matrix formatted for disease treatment, laboratory testing, physical examination, oxygen saturation monitoring, ambulation, diet, patient education and clinical outcome. Switch therapy reduced the period of intravenous antimicrobial administration from 7.6 days to 4.0 days (p < 0.0001). The period required to switch to oral antimicrobials decreased from 8.3 days to 4.8 days (p < 0.0001); hospital stay length, from 9.8 days to 6.5 days (p = 0.0001); and medical resource utilization, from 330, 373 to 227,768 Japanese yen (p = 0.0002). No patient from either group required readmission. In conclusion, Switch therapy was more efficient than management with a clinical pathway for mild to moderate community-acquired pneumonia in hospitalized patients.


Asunto(s)
Infecciones Comunitarias Adquiridas/terapia , Vías Clínicas , Neumonía/terapia , Administración Oral , Adulto , Anciano , Antibacterianos/administración & dosificación , Vías Clínicas/economía , Eritromicina/administración & dosificación , Femenino , Humanos , Infusiones Intravenosas , Tiempo de Internación/economía , Masculino , Persona de Mediana Edad , Minociclina/administración & dosificación , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA